Publication | Open Access

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Lymphoid NeoplasiaUrologyFebuxostat Versus AllopurinolMedicineKidney FailureHematologyClinical TrialsPathologyTumor Lysis SyndromeDialysis TherapyHigh Tls RiskOncologyRadiation OncologyCancer ResearchHealth Sciences